SLC5A2 and type 2 diabetes mellitus: Among these drugs, orally administered dapagliflozin (DAPA) is a highly selective and potent oral inhibitor of SGLT2, which has been used in patients with type 2 diabetes, improving glycemic control with minimal hypoglycemia, and is also associated with weight loss and systolic blood pressure (SBP) reduction.